Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00644358 · ClinicalTrials.gov registry record · Phase 3
A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 616
- Enrollment target
NCT00644358 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 616 participants.
The verdict
NCT00644358, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 616 participants
- Enrollment target
Study Summary
This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.
Interventions
- DRUG vilazodone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2007-12-31 |
| Est. Completion | 2009-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00644358
The ClinicalTrials.gov registry entry for NCT00644358 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 616 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vilazodone is the first listed.
NCT00644358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00644358 about?
NCT00644358 is a clinical study titled "A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)". This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.
What is the current status of trial NCT00644358?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 616 participants. The study started on 2007-12-31. Estimated completion is 2009-05-31.
What interventions are being tested in trial NCT00644358?
The interventions under investigation include: vilazodone (DRUG).
Who is sponsoring clinical trial NCT00644358?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.